Erasca “announced it has entered into exclusive license agreements for two preclinical RAS programs-a potential best-in-class pan-RAS molecular glue, ERAS-0015, and a potential first-in-class pan-KRAS inhibitor, ERAS-4001, and provided a pipeline update. ERAS-0015 and ERAS-4001 are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant tumors, of which over 2.2 million patients are diagnosed with KRAS-mutant tumors.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca Announces Pricing of Underwritten Offering of Common Stock
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
- Erasca files to sell 21.07M shares of common stock for holders
- Erasca reports Q1 EPS (23c), consensus (20c)
- Erasca Reports First Quarter 2024 Business Updates and Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue